TrialBrain communications2025

Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial.

Burak Yulug et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.